Cancer Institute A national cancer institute
designated cancer center

GI Cancer Clinical Trials & Research

Make a gift now - click hereThe Stanford Gastrointestinal (GI) Cancer Program always has new clinical trials beginning. Consult with your doctor about joining a clinical trial.

Current Research

The Stanford team is currently conducting trials of targeted agents in gastroesophageal, colorectal, pancreatic, GIST, and neuroendocrine tumors.

For patients with early stage pancreatic cancer, a Phase III trial is testing a novel vaccine in combination with standard chemotherapy or chemoradiation.

Recent GI Cancer Research Breakthroughs

Stanford doctors conducted several of the key trials that led to the widespread use of targeted therapies for GI cancers, including angiogenesis inhibitors for colorectal, neuroendocrine, and hepatocellular cancer and epidermal growth factor receptor (EGFR) inhibitors that are now routinely used in colorectal cancers.

In the News

Protein complex plays role in suppressing pancreatic tumors, study shows

Technologies give high-resolution ‘snapshot’ of cancer tissues

The Stanford Cancer Center has a total of 13 different multi-specialty tumor boards, each specializing in a different type of cancer. Learn more about our Cancer Tumor Boards.

Stanford Medicine Resources:

Footer Links: